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Assays that detect antibody to hepatitis C virus (HCV) are used to screen blood donors and patients with
hepatitis. Current enzyme-linked immunosorbent assay (ELISA)-based methods are invariably based upon
antigens from expressed recombinant proteins or oligopeptides from HCV type 1. Some HCV antigens used in
screening assays are coded by regions of the HCV genome that show extensive variability; therefore, HCV type
1-based assays may be less effective for the detection of antibody elicited by infection with other genotypes. In
this study, we have measured antibody reactivity of sera from 110 hepatitis C patients infected with type 1b,
3a, or 4a to genotype-specific and cross-reactive epitopes present in recombinant proteins from HCV genotypes
1b (core, NS3, and NS5), 3a (NS3, NS5), and 4a (core, NS3), corresponding to those used in current third-
generation screening ELISAs. By comparing the serological reactivities of sera to type-homologous and type-
heterologous antigens, we detected a significant type-specific component to the reactivity to NS3 (61 to 77% of
the total reactivity) and NS5 (60% of the total reactivity). Furthermore, despite the similarities in the amino
acid sequences of the core antigens of type 1b and type 4a, we also found significantly greater reactivity to
type-homologous antigens, with approximately 25% of reactivity being type specific. These findings are con-
sistent with previous findings of fivefold weaker reactivity of sera from HCV type 2- and HCV type 3-infected
blood donors in the currently used third-generation ELISAs and suggest that these assays are suboptimal for
screening populations in which the predominant genotype is not type 1.
Detection of antibody to hepatitis C virus (HCV) has be-
come the principal method for the diagnosis of HCV infection
in individuals with chronic hepatitis and for the screening of
blood donors. Although the original assay based upon the
c100-3 recombinant proteins derived from NS4 showed non-
specificity and insensitivity, the more recently developed assays
that use recombinant proteins from the core and NS3 regions
of the HCV genome (second-generation assays) and the NS5
region of the HCV genome (third-generation assays) have
proved to be more effective for the screening of blood donors.
Their use has led to a substantial reduction in the incidence of
posttransfusion hepatitis. In prospective studies, the incidence
of HCV transmission among recipients of blood screened by
first-generation assays was 1.5% in Spain (15), 3.7% in Japan
(27), and 11% in Taiwan (6). Screening by second-generation
assays reduced or would have reduced the incidence to 0.9% in
Japan (27), 1% in Spain (15), 2% in Greece (20), and 2.5% in
Taiwan (6).
One reason for the failure to detect antibody to HCV in
donated blood specimens that transmit HCV infection is that
the blood was collected from an individual with acute infection
before seroconversion for antibody. This so-called “window”
period is long for HCV compared with other viruses for which
blood from donors is screened, such as human immunodefi-
ciency virus, with means of 88 to 66 days in second- and third-
generation assays, respectively (9). By measuring the incidence
of HCV infection in blood donors, it has been estimated that
the current residual risk of HCV transmission through collec-
tion of “window” samples is 1 per 100,000 donations in the
United States (24). This frequency of infection is similar to the
residual risk of infection from blood screened by third-gener-
ation assays from French blood donors (10).
In addition, samples false negative for antibody have been
reported for a small proportion of immunocompetent individ-
uals persistently infected with HCV (2, 17). Indeed, even in
anti-HCV-positive individuals, there is considerable variability
in the frequency of reactivity to the individual HCV proteins
used in supplementary assays, such as the Ortho 3rd genera-
tion recombinant immunoblot assay (RIBA-3), and in the titer
of antibody to HCV among persistently infected individuals.
Among 90 anti-HCV-positive blood donors, antibody reactivity
in the Ortho third-generation screening assay varied over a
range of 5,000-fold, with some serum samples having antibody
levels only just above the cutoff for the assay (12).
HCV can be classified into at least six major genotypes,
whose nucleotide and inferred amino acid sequences over the
whole genome differ by approximately 30%. This degree of
amino acid sequence variability is similar to that observed
between variants of other RNA viruses (e.g., dengue virus
types 1 to 4), in which significant antigenic differences have
been documented and which form the basis of their classifica-
tion into serotypes. We have previously measured the serolog-
ical reactivities of individuals infected with different HCV ge-
notypes to antigens used in two third-generation anti-HCV
assays (Ortho 3rd generation anti-HCV EIA; Murex VK48).
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Samples from HCV type 1-infected individuals showed an ap-
proximately five times greater reactivity than those infected
with HCV type 2 or 3, and the reactivity was independent of
other factors that may have influenced the antibody response,
such as the degree of viremia, donor age, and severity of
hepatitis as assessed by alanine aminotransferase measure-
ments.
In the current study we have addressed two of the main
shortcomings of the first study. First, we have measured sero-
logical reactivities to the individual component antigens used
in a third-generation assay (core, NS3, and NS5). These mea-
surements extend previous investigations of type-specific and
cross-reactive serological reactivity to the NS4 antigen used in
the first-generation screening assays and in second- and third-
generation confirmatory assays (1, 5, 14, 21, 26, 28). Second, we
have carried out titrations with antigens derived from HCV
type 1 as well as corresponding proteins from other HCV
genotypes (types 3a and 4a). This allows levels of antibodies to
both type-homologous and type-heterologous antigens to be
measured, allowing for a more rigorous assessment of the
relative levels of type-specific and type-common reactivity to
each.
MATERIALS AND METHODS
Samples. Samples LJ516, EG21, and ED43 were obtained from individuals
infected with genotype 3a (LJ516) or 4a (EG21 and ED43 [3, 25]). Sequences
amplified from the core, NS3, and NS5 regions of types 3a and 4a were used for
the synthesis of antigens for antibody screening. Recombinant antigens from the
core (amino acid positions 1 to 140), NS3 (amino acid positions 1360 to 1454),
and NS5 (amino acid positions 2234 to 2318) (numbered according to Choo et al.
[7]) regions of HCV-UK (type 1b) were derived from an existing, commercially
available anti-HCV assay (VK48).
Serum samples were obtained from 110 anti-HCV-positive individuals with
chronic hepatitis C attending hospital liver clinics in Edinburgh and London,
United Kingdom; Karachi, Pakistan; and Cairo, Egypt. Among the samples, we
selected 33 infected with genotype 1b, 34 infected with genotype 3a, and 43
infected with genotype 4a. Genotypes were identified by restriction fragment
length polymorphism analysis of the 59 noncoding region as described previously
(11).
Development of enzyme-linked immunosorbent assays (ELISAs) based upon
type 3a and 4a antigens. RNAs from samples LJ516 (type 3a), EG21 (type 4a),
and ED43 (type 4a) were extracted as described previously (16): Reverse tran-
scription was carried out with avian myelobastosis virus reverse transcriptase and
RNasin (both from Promega, Southampton, United Kingdom), in each case by
using the external antisense primer, and incubation at 42°C for 30 min as de-
scribed previously (4). The sequences were amplified by using the following heat
cycle: 94°C for 18 s, 45°C for 21 s, and 72°C for 90 s for 30 cycles, followed by 6
min at 72°C with the primers listed in Table 1. The core region of type 4a was
amplified with primers 954 and 410, followed by amplification with primers D236
and 597. The NS3 region was amplified with primers 751 and 753, followed by
amplification with primers 594 and 593 (type 3a) or 750 and 007 and then primers
594 and 593 (type 4a). For the type 4a NS3 region, a third PCR was carried out
with the product of the second PCR by using the same inner primers. The NS5
region of genotype 3a was amplified by using primers 991 and 993, followed by
amplification with primers 3155 and 3156. The amplified sequences were cloned
and sequenced as described previously (23).
Expression of recombinant proteins. The sequences of the core, NS3, and NS5
regions from the different HCV genotypes indicated above were subcloned into
Escherichia coli or baculovirus expression vectors, as appropriate, by standard
molecular biology techniques. The NS3 and NS5 sequences of each genotype
were cloned into the E. coli vector pTrcHis (Invitrogen BV, Leek, The Nether-
lands) and were expressed in TOP10 cells by standard isopropyl-b-D-thiogalac-
topyranoside induction. Core sequences were cloned into the baculovirus expres-
sion vector pBlueBacHis2 (Invitrogen), and recombinant virus was derived by
cotransfection into insect cells along with linear Antographa californica nuclear
polyhedrosis virus DNA. Recombinant antigens were produced in Sf.9 insect
cells in an LH Series 210 bioreactor by infection at multiplicity of infection of 2
for 48 h.
Both the E. coli and baculovirus vector expression vectors place a tract of six
histidine residues at the amino terminus of each recombinant protein. Recom-
binant proteins were therefore subsequently prepared by metal chelate chroma-
tography on Probond nickel affinity resin (Invitrogen) to approximately 90%
purity.
ELISA for detection of antibody to core, NS3, and NS5 regions. To optimize
plate coating, purified antigens were titrated to levels giving acceptable specificity
and sensitivity and approximately equivalent amounts of protein per well (25 to
50 ng). Binding of antigen was assessed both by functional enzyme immunoassay
(EIA) with positive and negative sera and by probing for the histidine tag present
on each protein by using horseradish peroxidase chemically modified to bind
nickel ions. All antigens were coated overnight in 50 mM Tris (pH 8.5) contain-
ing 0.02% sodium dodecyl sulfate. The plates were then blocked by the addition
of 2% degraded gelatin and were finally dried to ensure stability.
For each antigen assay, each serum sample was diluted 1:10, 1:40, 1:160, and
1:640 in anti-HCV-negative sera. Aliquots of 20 ml from each titration were
added to 180 ml of sample diluent, mixed, and then added to a well of the ELISA
plate. A solution of 1:50 E. coli blocker was added to the diluent for all assays for
NS3 genotype 3a antigen. The plates were then incubated at 37°C for 1 h,
followed by five washes in glycerate-borate buffer. Bound antibody was detected
by the addition of 100 ml of horseradish peroxidase-labelled antibody to human
immunoglobulin G conjugate and by incubation for 30 min at 37°C. After wash-
ing, 100 ml of 3,39,5,59-tetramethylbenzidine substrate was added, and the mix-
ture was incubated for 30 min at 37°C. The color development reaction was
stopped by the addition of 50 ml of 2 M H2SO4, and optical densities (ODs) were
measured at 470 nm. All assay plates included a dilution series of the reference
genotype 1a sample (dilutions of 1:2 to 1:2,560) for calculation of antibody levels.
The NS3 genotype 3a recombinant antigens were expressed in E. coli and re-
quired the addition of 1:50 E. coli blocking solution in the sample diluent for all
assays.
Quantification of antibody levels. Antibody reactivity to each recombinant
protein in each of the test serum samples was determined by titration and
reference to a standard positive control as described previously (12). This
method is based upon the observation of a linear relationship between OD (over
the range of values of 0.02 to 1.0) and concentration of antibody in both ELISAs
based upon single antigens, as in the current study and in the currently used
third-generation screening assays from Ortho and Murex (12). Because of this
relationship, the antibody reactivity of a test sample can be expressed relative to
that of a reference control by the following formula: test antibody level 5 (test
OD 3 reference concentration)/(reference OD 3 test concentration). Antibody
levels were obtained for each sample in each antigen assay in this way.
Estimation of relative proportions of type-specific and cross-reactive antibod-
ies. The ratio of antibody levels measured to type-homologous and type-hetero-
logous antigens indicates the relative proportions of type-specific and cross-
reactive reactivities. This calculation is complicated by the possible existence of
differences in the antigenicity or presentation of proteins from different geno-
types in the ELISA and differences in antibody levels elicited by infection with
different genotypes.
The proportion of antibody reactivity that is cross-reactive between genotypes
is measured by reciprocal assays of reactivity between sera and antigens from two
genotypes, genotypes A and B. In the following relations, EBA represents the
antibody reactivity of a serum sample infected with genotype B with antigen of
genotype A, AAB is the overall antigenicity of the genotype A antigen relative to
that of the genotype B antigen, and Tc and Ts are the proportions of the antibody
response that are type common and type specific, respectively, such that Tc 1
Ts 5 1.
EBB
EBA
5
EBB
EBB 3 AAB 3 Tc
5
1
AAB 3 Tc
EAB
EAA
5
EAA 3 ~1/AAB! 3 Tc
EAA
5
Tc
AAB
TABLE 1. Primers used for amplification of core,
NS3, and NS5 regions
Primer no. Sequencea
954 ..............ACT GCC TGA TAG GGT GCT TGC GAG
410 ..............GAG CGG AAT GTA CCC CAT GAG GTC GGC
D236...........GGT AGA CCG GAT CCC ATG AGC ACG AAT CCT AAA
597 ..............GAA AGA AGC TTA GAC GAG CGG AAT GTA CCC
751 ..............TTY CGG GCN GCY GTG TGC ACC
753 ..............GCG TCA TAG CAC TCA CAG AGG AC
594 ..............ACC RCT GCA GAY CCY AAC ATN GAG GAR GT
593 ..............CAC AAG CTT ARC AGT AGT CKA TSA CNG ART C
750 ..............TGG TYA CNN GNN AYG CYG ATG TCA TYC C
007 ..............ACC TCG AGT ATC CCA CTG ATG AAG TTC CAC AT
991 ..............TGG CNA GCT CNT CNG CNA GCC A
993 ..............GGC TCC CCC TCA AGG GRG GCA TRG A
3155 ............GGA TCC AAY ATN ACY CGY GTR GAG TCW SA
3156 ............AAG CTT GTG GTG GYA AGG CAC AYC C
a International Union of Pure and Applied Chemistry ambiguity codes were
used: Y, C/T; R, A/G; N, G/C/A/T; K, G/T; S, C/G; W, A/T. Cleavage sties for
restriction enzymes are underlined: CTGCAG, PstI; AAGCTT, HindIII; GGA
TCC, BamHI.
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Therefore,
EBB/EBA
EAB/EAA
5
AAB
AAB 3 ~Tc!2
5
1
~Tc!2
From this the proportion of type-common reactivity can be derived as follows:
Tc 5 ÎEAB/EAAEBB/EBA
and
AAB 5 Î 1~EAA/EAB! 3 ~EBA/EBB!
These relations make the assumption that the relative proportions of type-
specific to type-common reactivity in a type A antiserum are the same as those
found in a type B antiserum.
Nucleotide sequence accession numbers. The sequences obtained in the
course of this project have been submitted to GenBank and bear the following
accession numbers: DX387, AFO29298; DX506, AFO29297; DX499,
AFO29296; DX507, AFO29299.
RESULTS
Variability of core, NS3, and NS5 region sequences. The
amino acid sequences of the recombinant proteins used in the
ELISA were deduced from the nucleotide sequences of the
corresponding clones and were compared with other published
sequences of these regions of HCV (Fig. 1). In the core protein
only 9 amino acids differed between genotypes 1b and 4a over
the 140-amino-acid length (6% divergence). Substitutions were
generally conservative, where only one resulted in a change in
the ionic charge. The NS3 sequences exhibited more variabil-
ity, with the sequence of genotype 1b differing from that of
genotype 3a by 15 of 95 amino acids (16% divergence) and
from that of genotype 4a by 13 amino acids, while genotypes 3a
FIG. 1. Comparison of the inferred amino acid sequences of antigens expressed from recombinant clones of (A) core (HCVUPCP, type 1b; DX387, type 4a), (B)
NS3 (HCVUPCP, type 1b; DX506, type 3a; DX499, type 4a), and (C) NS5 regions (HCVUPCP, type 1b; DX507, type 3a) with representatives of each of the major
HCV genotypes and subtypes. Periods indicate identity with the HCV prototype sequence, HCV-PT (7). Numbers refer to amino acid positions on HCV-PT.
3064 NEVILLE ET AL. J. CLIN. MICROBIOL.
and 4a differed from each other by 14 amino acids. In the NS5
sequence there were 23 differences between genotypes 1b and
3a over a length of 85 amino acids (27% divergence). Six of
these substitutions affected the charge of the protein: four
substitutions of nonpolar amino acids for basic groups and two
substitutions of acidic groups for nonpolar groups.
Quantitation of antibody reactivity to core, NS3, and NS5
antigens. The serological reactivities of sera from 33 individ-
uals with genotype 1b, 34 individuals with genotype 3a, and 43
individuals with genotype 4a HCV infections to each of the
recombinant antigens from genotypes 1b, 3a, and 4a were
measured. To investigate the reproducibility of the method
used to quantify antibody levels, each of the serum specimens
was assayed in replicate against the type 1b and 4a core pro-
teins (Fig. 2). A close correlation was observed between the
two measured antibody levels, with nonparametric correlation
coefficients being 0.877, 0.889, and 0.862 for type 1b, 3a, and 4a
antisera, respectively. For the type 4a core antigens, the cor-
responding correlation coefficients were 0.784, 0.721, and
0.802.
There was also a close correlation between reactivity to the
core protein of type 1b and that to type 4a (Table 2), with
correlation coefficients of 0.834, 0.765, and 0.767 for type 1b,
3a, and 4a antisera, respectively. Significant correlations were
also consistently observed between the reactivities of antisera
to NS3 proteins of types 1b, 3a, and 4a, as well as between the
reactivities of antisera to NS5 proteins of type 1b and 3a. In
contrast, there was little if any correlation between antibody
reactivity to different regions of the genome. For example, the
reactivity of sera from type 1b-infected individuals to the type
1b core protein showed no correlation with reactivity to type 1b
NS3 or NS5 proteins (correlation coefficients, 20.118 and
20.181, respectively; Table 2). The only exceptions were weak
correlations (0.443 and 0.471) between the reactivities to 3a
NS3 and NS5 (but only for type 1b sera) and between NS5 of
type 1b with NS3 of 4a (restricted to type 3a sera).
FIG. 1—Continued.
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Genotype dependence of serological reactivity. Sera col-
lected from individuals infected with different genotypes varied
in their frequency of reactivity to NS3 and NS5 antigens of
different genotypes (Table 3). For NS3, frequencies of reactiv-
ity for type 1b, 3a, and 4a antisera to type-homologous NS3
proteins were 85, 100, and 76%, respectively, compared with a
range of 44 to 76% for type-heterologous combinations. Sim-
ilarly, the frequency of reactivity of type 1b sera with type 1b
NS5 antigen (65%) was higher than that of heterologous sera
(47 and 51%), as was reactivity to type 3a NS5 (58% type-
homologous reactivity, compared with 24 and 45% for type-
heterologous combinations). In the core region, high frequen-
cies of reactivity were observed for both type-homologous (95
to 97%) and type-heterologous (86 to 97%) combinations, indi-
cating the greater antigenicity of this region of the genome and/or
a greater proportion of shared epitopes between genotypes.
To compare the strength of reactivity with type-homologous
and type-heterologous antigens, antibody levels relative to
those for the positive control calculated from OD readings at
dilutions ranging from 1:10 to 1:640 were used to calculate
antibody levels relative to those for the positive control (Fig.
3). There were significant differences in antibody reactivity to
the type 1b core protein between samples from individuals
infected with genotype 1b and those from individuals infected
with genotype 4a (P 5 0.033) but not those with genotype 3a
(P 5 0.811). The distribution of antibody levels directed to the
genotype 4a core antigen showed no significant difference be-
tween genotypes.
Antibody reactivity against NS3 was frequently undetectable
among sera from individuals infected with HCV with type-
heterologous antigen (Table 3; Fig. 3C). The distribution of
levels of antibody to type-homologous antigens was consis-
tently greater than those to type-heterologous antigens. For
example, the median level of antibody to type 1b NS3 in type
1b sera was 0.225, which was substantially greater than the
median reactivities of type 3a and 4a sera to this protein (0.003
[P 5 0.004] and 0.02 [P 5 0.005], respectively). Similar, pre-
dominant type-specific reactivities against type 3a and 4a an-
tigens were observed (Fig. 3D and E).
Only 54% of the samples reacted with the NS5 genotype 1b
antigen and 43% reacted with the genotype 3a antigen. The
median antibody level of genotype 1b sera (0.031) was eight-
fold higher than that for type 3a samples (0.004) and threefold
higher than that for type 4a (0.012). The distribution of anti-
body levels among genotype 1b samples was significantly
higher than that among genotype 4a samples (P 5 0.029) but
not genotype 3a samples. The reactivity of type 3a sera against
FIG. 2. Measurement of the reproducibility of measurement of levels of
antibody to type 1b (A) and type 4a (B) core protein by sera from study subjects
by repeat testing. The correlation is indicated by a regression line.
TABLE 2. Correlation between reactivity to different antigens
Antigen
and geno-
type
HCV
genotype
in serum
Correlation for the following antigens
and genotypesa:
Core NS3 NS5
1b 4a 1b 3a 4a 1b 3a
Core
1b 1b (1)
3a (1)
4a (1)
4a 1b 0.834 (1)
3a 0.765 (1)
4a 0.767 (1)
NS3
1b 1b 20.118 0.023 (1)
3a 0.133 0.279 (1)
4a 0.100 20.035 (1)
3a 1b 20.270 20.066 0.456 (1)
3a 0.153 0.274 0.363 (1)
4a 0.159 0.030 0.627 (1)
4a 1b 0.048 0.224 0.710 0.518 (1)
3a 0.215 0.130 0.570 0.393 (1)
4a 20.058 20.087 0.497 0.272 (1)
NS5
1b 1b 20.181 20.220 0.150 0.275 0.157 (1)
3a 0.066 0.000 0.218 0.265 0.471 (1)
4a 0.058 20.192 0.069 0.168 0.055 (1)
3a 1b 20.141 20.43 0.247 0.443 0.348 0.630 (1)
3a 0.051 0.172 0.216 0.266 0.202 0.649 (1)
4a 20.076 20.108 0.186 0.179 0.041 0.303 (1)
a Correlation is indicated by Spearman’s rank correlation coefficient. Separate
values are provided for antisera of each genotype. Significant values (P , 0.05)
are underlined.
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NS3 of genotype 3a was significantly greater than that of the
type 1b or 4a sera (P 5 0.002 and 0.01, respectively).
Ratio of type-specific and cross-reactive reactivities. The
ability to measure the reactivity of the same antiserum to
antigens of different genotypes allowed for an estimation of the
relative levels of genotype-specific and cross-reactive serolog-
ical reactivities. For the core proteins, the levels of antibody to
the genotype 1b antigen in each of the type 1b and 4a sera were
FIG. 3. Distribution of antibody reactivity of sera from individuals infected with type 1b, 3a, and 4a to core proteins of genotypes 1b and 4a (A and B, respectively);
NS3 of genotypes 1b, 3a, and 4a (C, D, and E respectively); and NS5 of types 1b and 3a (F and G, respectively). Median values are indicated by short horizontal bars.
Pairwise comparison of the distributions of values was carried out by the nonparametric Kruskall-Wallis test.
TABLE 3. Frequency of reactivity to core, NS3, and NS5 proteins
Antiserum
No. of specimens reactive to the following antigen/total no. of specimens (%):
Core NS3 NS5
1b 4a 1b 3a 4a 1b 3a
Type 1b 32/33 (97) 32/33 (97) 28/33 (85) 25/33 (76) 24/32 (76) 21/33 (64) 8/33 (24)
Type 3a 33/34 (97) 30/34 (88) 15/34 (44) 33/33 (100) 9/33 (27) 16/34 (47) 18/31 (58)
Type 4a 37/43 (86) 41/43 (95) 31/43 (72) 27/43 (63) 31/41 (76) 22/43 (51) 19/42 (45)
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divided by their levels to the genotype 4a antigen (Fig. 4; Table
4). The median ratio of reactivity to type 1b/reactivity to type
4a antigens for type 1b antisera was 1.49, compared with a
median ratio of 0.809 for the type 4a antisera. This indicates
that type 1b sera react more strongly against the type 1b (ho-
mologous) core protein, while the type 4a sera react slightly
more strongly against the type 4a antigen. If it were shown that
both core proteins were coated equivalently on the solid phase
and showed equal antigenicity, then the type-specific reactivity
to these proteins could be calculated from the difference from
the ratio of 1 that would be expected from exclusively type-
common reactivity. However, it is possible that some antigens
are present at higher available concentrations than others
through differences in binding to the solid phase or solubility.
These differences were taken into account by using the deri-
vation described in Materials and Methods. In this instance,
the term EAB/EAA represents the median of the ratio of reac-
tivity between type 4a antisera with type 1b and type 4a anti-
gens (0.809). The term EBB/EBA is similarly represented by the
median ratio of the type 1b antisera (1.49). Therefore, the
proportion of type-common reactivity can be calculated as
0.74, with type-specific reactivity forming the remainder of the
reactivity (0.26).
The median ratio of reactivity of the type 3a sera to type 3a
and 1b NS5 antigens (0.654) was substantially lower than that
of type 1b sera (median, 4; Table 4). Therefore, the propor-
tions of type-common and type-specific reactivity were 40 and
60%, respectively; i.e., the majority of the serological reactivity
to this antigen was type specific. Finally, three sets of pairwise
comparisons can be made for the NS3 region, in which anti-
gens for all three genotypes were available. Sixty-two percent
of the serological reactivity between type 1b and 3a proteins
was type specific, similar to the proportions of 61% between
type 1b and 4a proteins and 77% between type 3a and 4a
proteins (Table 4).
DISCUSSION
Antigenic variability of HCV. The aim of this study was to
investigate the degree of type-specific serological reactivity to
antigens used in current, third-generation screening assays.
The use of recombinant antigens expressed from different ge-
notypes in the enzyme immunoassay allowed reciprocal mea-
surements of type-homologous and type-heterologous reactiv-
ity to be made, and these provided a more rigorous assessment
of the type-specific components of reactivity to the core, NS3,
and NS5 regions. This addresses a potential criticism of previ-
ous investigations that showed weaker reactivity of sera from
individuals infected with non-type 1 genotypes in either of the
screening ELISAs or to individual antigens in the confirmatory
recombinant immunoblot assay (5, 8, 12, 14, 21, 28), in that
there is a possibility that these observations resulted from a
generally weaker serological response to infection than that
elicited by type 1. In the current study we were able to consis-
tently show stronger reactivity of sera to antigens of a homol-
ogous type than to antigens of heterologous types.
From pairwise reciprocal measurements of antibody reactiv-
ity (such as type 1b and 4a antisera against type 1b and 4a
antigen), it was possible to quantify the relative contributions
of type-specific and cross-reactive antibody reactivities by using
the relation derived in Materials and Methods (Table 4). These
calculations were independent of possible differences in the
strength of the serological response elicited by infection with
different genotypes and were also independent of differences in
antigen concentration or overall antigenicity between proteins
of different genotypes (expressed as the ratio AAB). This re-
moves the potential criticism that the coating efficiency of
antigens from different genotypes onto the solid phase was not
compared prior to measurement of antibody levels. From this
analysis we found a relationship between the degree of amino
acid sequence divergence between recombinant proteins and
their degree of cross-reactivity. The sequence of the core pro-
tein was the most conserved and the core protein showed
approximately 25% type-specific reactivity, while the more di-
vergent sequences, those of the NS3 and NS5 regions, showed
substantially greater proportions of type-specific reactivity.
These results are consistent with previous comparisons of the
type-specific component of reactivity to peptides correspond-
ing to linear epitopes in NS4. By absorption in solution with
peptides of heterologous genotypes, it was shown that reactiv-
ity to type-homologous peptides was reduced but was rarely
eliminated (1, 26), allowing development of a sensitive and
specific serological typing assay. The type-specific component
of serological reactivity to NS4 and, in some studies, to the core
protein has been also used in typing assays without cross-
absorption, because it has consistently been observed that re-
activity to type-homologous antigens in these (13, 19, 22) and
other regions (29) is stronger.
Implications for screening assays. The effect of the demon-
strated antigenic variabilities of the components of third-gen-
FIG. 4. Ratios of reactivity of type 1b and 4a sera to type 1b/type 4a core
antigens. Median ratios are indicated by short horizontal bars. Pairwise compar-
ison of the distributions of values was carried out by the Kruskall-Wallis test.
Ratios of reactivities to other antigens are presented in Table 4.
TABLE 4. Type-specific and type-common serological reactivity
to HCV core, NS3, and NS5 antigens
Region
Anti-
serum Median ratio
a
P valueb
Percent
A B A B Tc Ts
Amino aid
divergencec
Core 4a 1b 0.809 1.49 ,0.001 74 26 6.4
NS5 3a 1b 0.654 4.0 0.014 40 60 27
NS3 3a 1b 0.053 0.373 0.001 38 62 16
4a 1b 0.016 0.107 ,0.001 39 61 14
4a 3a 0.049 0.939 ,0.001 23 77 15
a Ratio of reactivity to antigens of genotypes A and B.
b Comparison of the distribution of ratios of reactivity of individual antisera to
antigens of genotypes A and B by the Kruskall-Wallis nonparametric test.
c Degree of amino acid sequence divergence between antigens of genotypes A
and B.
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eration screening assays on their overall sensitivity for screen-
ing is difficult to estimate with precision for two reasons.
Individuals vary in their serological responses to different an-
tigens, and therefore in the extent to which these responses
may result in cross-reactivity with antigens of heterologous
genotypes. For example, if reactivity were directed solely to the
core protein, this protein would cross-react with antigens of
heterologous genotypes, whereas sera monoreactive with NS3,
such as is found upon seroconversion, would be expected to be
predominantly type specific.
Furthermore, each of the three antigens investigated is likely
to contain a range of linear and conformational epitopes, and
these will vary in their degree of cross-reactivity. Recognition
of different epitopes in the antigens may be one explanation for
the wide range of ratios of reactivity to type-homologous and
type-heterologous antigens observed between sera of the same
genotype (Fig. 4). In the extreme case, it is possible that reac-
tivity confined to epitopes in the core protein that are type
specific would lead to poor or absent reactivity to the core
protein of other genotypes. Conversely, the high degree of
cross-reactivity observed between certain sera with NS3 or NS5
proteins of heterologous genotypes may have resulted from
their recognition of shared epitopes.
The observed differences in reactivity of sera to homologous
and heterologous proteins would only lead to false-negative
results on serological screening if antibody levels in samples to
be tested were close to the cutoff sensitivity of the assay. In a
previous study, we measured antibody reactivity in the Ortho
third-generation assay and found a wide range of antibody
levels (approximately 5,000-fold) among samples from blood
donors infected with genotypes 1, 2, and 3, with the lowest level
found to be 0.0007, which is just above the cutoff value of the
test (12). Low antibody levels and reactivity to a restricted
range of epitopes, such as those in NS3, are found in acutely
infected individuals (18), and it is likely that earlier detection
of seroconversions, and therefore a reduction in the window
period associated with non-type 1 infection, may be achieved
by assays containing NS3 and other antigens from a wider
range of genotypes.
The finding of significant antigenic variability of antigens
used for serological screening will form the basis for a number
of future investigations. Now that antigens from other geno-
types have been produced, it will be possible to carry out
large-scale screening of populations infected with non-type 1
genotypes (for example, with the type 4a antigens for testing
individuals in the Middle East). This may reveal the frequency
with which anti-HCV samples are being missed by conven-
tional assays and may ultimately help reduce the frequency of
posttransfusion hepatitis further, particularly when popula-
tions with a high frequency of acute infection are screened.
Similarly, the incorporation of antigens from other genotypes
(particularly NS3) in confirmatory assays may resolve the re-
sults for a number of the indeterminate samples identified in
blood donor screening and for which interpretation of results is
currently problematic.
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